Post-marketing surveillance of LUTATHERA Injection (All Case Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031220065

Enrollment

300

Registered

2022-05-17

Start date

2021-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Somatostatin receptor-positive neuroendocrine tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who received LUTATHERA Injection

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
1. Case composition Number of registered cases, number of cases for which questionnaires were collected, number of cases for safety analysis Number of cases excluded from analysis and reasons for exclusion 2. Safety items The rate of adverse drug reactions The rate of serious adverse drug reactions The rate of adverse drug reactions related to the safety specifications in this study 3. Others Treatment results with this drug	—

Measure

Time frame

1. Case composition Number of registered cases, number of cases for which questionnaires were collected, number of cases for safety analysis Number of cases excluded from analysis and reasons for exclusion 2. Safety items The rate of adverse drug reactions The rate of serious adverse drug reactions The rate of adverse drug reactions related to the safety specifications in this study 3. Others Treatment results with this drug

—

Contacts

Public ContactManager of Potmarketing surveillane

FUJIFILM Toyama Chemical Co., Ltd

fftc-lutathera-gpsp@fujifilm.com+81-3-5579-5768

Outcome results